Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resolaris in Adult FSHD
NCT02239224Phase 2Completed
- Sponsor
- aTyr Pharma
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of Resolaris in facioscapulohumeral muscular dystrophy (FSHD) (4 arms), sponsored by aTyr Pharma. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Positive Anti-Drug Antibodies and 2 more. Started Sep 2014; status: completed.
02
Drugs
Resolaris
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT02239224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239224.